Deepak Goyal

Ambulatory blood pressure monitoring in heart failure: a systematic review

Ambulatory blood pressure monitoring has established its use in the definition of white coat hypertension and monitoring of treatment of essential hypertension. Any role for ambulatory blood pressure monitoring in heart failure is not well defined. However, from the limited studies available, ambulatory blood pressure monitoring may be used to optimise heart failure therapy, and as a prognosis marker in this patient group.

Fondaparinux: an overview

Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring. Current evidence suggest that fondaparinux is as effective as, if not more than, enoxaparin in the prevention of venous thromboembolism in the postoperative period. It has also been found to have similar effectiveness to enoxaparin and unfractionated heparin in the treatment of venous and pulmonary embolism, respectively. In the field of cardiology, studies have demonstrated that in the setting of acute coronary syndromes, treatment with fondaparinux is not inferior to enoxaparin in preventing major cardiac outcomes, but it is associated with lower risk of bleeding complications, irrespective of the use of percutaneous coronary intervention. During percutaneous coronary intervention, there is a slightly increased risk of catheter thrombosis, which is removed when used along with unfractionated heparin. However, in patients with ST-elevation myocardial infarction, the benefit has been shown in those either receiving thrombolysis or not undergoing any revascularization, but not in subjects undergoing primary percutaneous coronary intervention where unfractionated heparin is still preferred.

Generalized Obesity but not that Characterized by Raised Waist‐Hip Ratio Is Associated with Increased Perceived Breathlessness During Treadmill Exercise Testing

The management of obesity is linked to defining its impact on exercise. One impact of obesity in coronary disease care is in the quantification of exercise limitation by treadmill protocols. In this study, we considered the impact of obesity as definition by body mass index (BMI) or waist-hip ratio (WHR) on perceived exercise limiting symptoms, which are accepted and valuable targets for drug or lifestyle modification. We gathered morphometric data prospectively using bioimpedance (Bodystat Quadscan 3000), BMI, and WHR in 228 unselected cardiac patients attending for diagnostic Bruce treadmill tests. The patients were categorized as obese (BMI >30 kg/m(2)), overweight (BMI 25.0-29.9 kg/m(2)), or normal weight (BMI <25 kg/m(2)). A quantitative visual analog scale (10 cm) of perceived breathlessness was defined by the subjects at the end of each stage along with standard exercise data. In total, 188 patients were included for the final analysis excluding 12 patients with severe LV dysfunction and 10 patients with severe inducible ischemia necessitating an early termination of the test. There was no difference by obesity indices in the distribution of reasons for stopping the test (elective arrhythmia, inducible ischemia, or intolerable functional symptoms). Perceived symptom score on the visual analog scale were persistently higher at the end of stages 1, 2, and 3 of the Bruce protocol in obese individuals as compared with overweight and normal weight subjects. (P= 0.034, 0.003, and 0.042, respectively). Perceived symptoms during exercise when assessed by WHR did not show any statistical difference in severity. Generalized obesity associated with a high BMI is associated with increased perceived breathlessness during standard exercise testing regardless of ischemia or known left ventricular systolic function. This clearly indicates that perceived breathlessness does not correlate with obesity as defined by WHR, which is known to be a more sensitive marker of coronary disease. Therapeutic interventions in obesity should take into account the frame of reference of definition of obesity.

Diastolic heart failure: recognition, diagnosis and management.

A variety of community-based epidemiological studies have suggested that 30 – 50% of patients with heart failure symptoms appear to have preserved left ventricular (LV) systolic function when assessed by echocardiography or similar techniques suggesting ‘diastolic heart failure’ (DHF) as its cause. The prognosis of these patients is characterised by morbidity and mortality similar to, but less overt than, patients with systolic dysfunction. However, rates of readmission for symptom control are broadly similar in patients with DHF or in those with systolic impairment. Thus, there are many similarities in the portrayal of both systolic and DHF but equally; there are also many key differences. Certainly, while there are several successful therapies for patients with systolic heart failure, the management of patients with DHF is poorly defined. In this review, the gaps in current knowledge and practice, which is creating this therapeutic void will be addressed.

Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies.

Purpose of review Thrombotic complications are a common cause of morbidity and mortality in patients with gynaecological or advanced breast malignancies. There are several manifestations of thromboembolism in these patients, but deep venous thrombosis of the legs is the usual presentation. This review highlights various manifestations of thrombotic complications in these malignancies, and also describes the current evidence base for various forms of thromboprophylaxis. Recent findings Several trials have suggested that low molecular weight heparin therapy is at least as effective as oral anticoagulation for secondary prophylaxis. It has also been suggested that low molecular weight heparin therapy may prolong survival in cancer patients, but this was not shown in the results of one recently published placebo-controlled randomized trial. Summary Primary thromboprophylaxis in cancer should be individualized and considered according to the risk category of each patient. Low molecular weight heparin therapy can be used for secondary thromboprophylaxis in patients with breast or gynaecological malignancy. However, more studies are needed to substantiate their acceptance in cancer patients. Abbreviations DIC: disseminated intravascular coagulation; DVT: deep venous thrombosis; INR: international normalized ratio; IPC: intermittent pneumatic calf compression; LMW: low molecular weight.